 | • レポートコード：QFJ1-4607 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、腫瘍小分子薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（化学治療薬、免疫調節薬、標的治療薬、ホルモン療法、その他）、用途別市場規模（血液がん、乳がん、消化器がん、前立腺がん、肺がん、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・腫瘍小分子薬の市場動向 ・企業の競争状況、市場シェア ・腫瘍小分子薬の種類別市場規模と予測2016-2027（化学治療薬、免疫調節薬、標的治療薬、ホルモン療法、その他） ・腫瘍小分子薬の用途別市場規模と予測2016-2027（血液がん、乳がん、消化器がん、前立腺がん、肺がん、その他） ・腫瘍小分子薬の北米市場規模2016-2027（アメリカ、カナダ） ・腫瘍小分子薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・腫瘍小分子薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腫瘍小分子薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・腫瘍小分子薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Roche、Novartis、Pfizer、Celgene、Bristol-Myers Squibb、Amgen、Johnson & Johnson、AbbVie、Sanofi、Takeda、Eli Lilly、Bayer、AstraZeneca、Astellas、Merck、Biogen Idec、Eisai、Teva、Otsuka、Ipsen、Gilead Sciences、Exelixis） ・結論 |
Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Cancer Treatment Drugs are used to treat malignancies, or cancerous growths.
Market Analysis and Insights: Global Oncology Small Molecule Drugs Market
The global Oncology Small Molecule Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oncology Small Molecule Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oncology Small Molecule Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oncology Small Molecule Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oncology Small Molecule Drugs market.
Global Oncology Small Molecule Drugs Scope and Market Size
Oncology Small Molecule Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oncology Small Molecule Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Chemotherapy Drugs
Immunomodulating Drugs
Targeted Therapy Drugs
Hormonal Therapy
Other
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Lung Cancer
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Roche
Novartis
Pfizer
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
AbbVie
Sanofi
Takeda
Eli Lilly
Bayer
AstraZeneca
Astellas
Merck
Biogen Idec
Eisai
Teva
Otsuka
Ipsen
Gilead Sciences
Exelixis
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Small Molecule Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy Drugs
1.2.3 Immunomodulating Drugs
1.2.4 Targeted Therapy Drugs
1.2.5 Hormonal Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Oncology Small Molecule Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Lung Cancer
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oncology Small Molecule Drugs Market Perspective (2016-2027)
2.2 Oncology Small Molecule Drugs Growth Trends by Regions
2.2.1 Oncology Small Molecule Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oncology Small Molecule Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Oncology Small Molecule Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Oncology Small Molecule Drugs Industry Dynamic
2.3.1 Oncology Small Molecule Drugs Market Trends
2.3.2 Oncology Small Molecule Drugs Market Drivers
2.3.3 Oncology Small Molecule Drugs Market Challenges
2.3.4 Oncology Small Molecule Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Small Molecule Drugs Players by Revenue
3.1.1 Global Top Oncology Small Molecule Drugs Players by Revenue (2016-2021)
3.1.2 Global Oncology Small Molecule Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Oncology Small Molecule Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oncology Small Molecule Drugs Revenue
3.4 Global Oncology Small Molecule Drugs Market Concentration Ratio
3.4.1 Global Oncology Small Molecule Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Small Molecule Drugs Revenue in 2020
3.5 Oncology Small Molecule Drugs Key Players Head office and Area Served
3.6 Key Players Oncology Small Molecule Drugs Product Solution and Service
3.7 Date of Enter into Oncology Small Molecule Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Small Molecule Drugs Breakdown Data by Type
4.1 Global Oncology Small Molecule Drugs Historic Market Size by Type (2016-2021)
4.2 Global Oncology Small Molecule Drugs Forecasted Market Size by Type (2022-2027)
5 Oncology Small Molecule Drugs Breakdown Data by Application
5.1 Global Oncology Small Molecule Drugs Historic Market Size by Application (2016-2021)
5.2 Global Oncology Small Molecule Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Oncology Small Molecule Drugs Market Size (2016-2027)
6.2 North America Oncology Small Molecule Drugs Market Size by Type
6.2.1 North America Oncology Small Molecule Drugs Market Size by Type (2016-2021)
6.2.2 North America Oncology Small Molecule Drugs Market Size by Type (2022-2027)
6.2.3 North America Oncology Small Molecule Drugs Market Size by Type (2016-2027)
6.3 North America Oncology Small Molecule Drugs Market Size by Application
6.3.1 North America Oncology Small Molecule Drugs Market Size by Application (2016-2021)
6.3.2 North America Oncology Small Molecule Drugs Market Size by Application (2022-2027)
6.3.3 North America Oncology Small Molecule Drugs Market Size by Application (2016-2027)
6.4 North America Oncology Small Molecule Drugs Market Size by Country
6.4.1 North America Oncology Small Molecule Drugs Market Size by Country (2016-2021)
6.4.2 North America Oncology Small Molecule Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Oncology Small Molecule Drugs Market Size (2016-2027)
7.2 Europe Oncology Small Molecule Drugs Market Size by Type
7.2.1 Europe Oncology Small Molecule Drugs Market Size by Type (2016-2021)
7.2.2 Europe Oncology Small Molecule Drugs Market Size by Type (2022-2027)
7.2.3 Europe Oncology Small Molecule Drugs Market Size by Type (2016-2027)
7.3 Europe Oncology Small Molecule Drugs Market Size by Application
7.3.1 Europe Oncology Small Molecule Drugs Market Size by Application (2016-2021)
7.3.2 Europe Oncology Small Molecule Drugs Market Size by Application (2022-2027)
7.3.3 Europe Oncology Small Molecule Drugs Market Size by Application (2016-2027)
7.4 Europe Oncology Small Molecule Drugs Market Size by Country
7.4.1 Europe Oncology Small Molecule Drugs Market Size by Country (2016-2021)
7.4.2 Europe Oncology Small Molecule Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Oncology Small Molecule Drugs Market Size (2016-2027)
8.2 Asia-Pacific Oncology Small Molecule Drugs Market Size by Type
8.2.1 Asia-Pacific Oncology Small Molecule Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oncology Small Molecule Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oncology Small Molecule Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Oncology Small Molecule Drugs Market Size by Application
8.3.1 Asia-Pacific Oncology Small Molecule Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Oncology Small Molecule Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Oncology Small Molecule Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Oncology Small Molecule Drugs Market Size by Region
8.4.1 Asia-Pacific Oncology Small Molecule Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oncology Small Molecule Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Oncology Small Molecule Drugs Market Size (2016-2027)
9.2 Latin America Oncology Small Molecule Drugs Market Size by Type
9.2.1 Latin America Oncology Small Molecule Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Oncology Small Molecule Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Oncology Small Molecule Drugs Market Size by Type (2016-2027)
9.3 Latin America Oncology Small Molecule Drugs Market Size by Application
9.3.1 Latin America Oncology Small Molecule Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Oncology Small Molecule Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Oncology Small Molecule Drugs Market Size by Application (2016-2027)
9.4 Latin America Oncology Small Molecule Drugs Market Size by Country
9.4.1 Latin America Oncology Small Molecule Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Oncology Small Molecule Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Small Molecule Drugs Market Size (2016-2027)
10.2 Middle East & Africa Oncology Small Molecule Drugs Market Size by Type
10.2.1 Middle East & Africa Oncology Small Molecule Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oncology Small Molecule Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oncology Small Molecule Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Oncology Small Molecule Drugs Market Size by Application
10.3.1 Middle East & Africa Oncology Small Molecule Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Oncology Small Molecule Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Oncology Small Molecule Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Oncology Small Molecule Drugs Market Size by Country
10.4.1 Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Oncology Small Molecule Drugs Introduction
11.1.4 Roche Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Oncology Small Molecule Drugs Introduction
11.2.4 Novartis Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Oncology Small Molecule Drugs Introduction
11.3.4 Pfizer Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Celgene
11.4.1 Celgene Company Details
11.4.2 Celgene Business Overview
11.4.3 Celgene Oncology Small Molecule Drugs Introduction
11.4.4 Celgene Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.4.5 Celgene Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Oncology Small Molecule Drugs Introduction
11.5.4 Bristol-Myers Squibb Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Oncology Small Molecule Drugs Introduction
11.6.4 Amgen Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.6.5 Amgen Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Oncology Small Molecule Drugs Introduction
11.7.4 Johnson & Johnson Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.7.5 Johnson & Johnson Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Oncology Small Molecule Drugs Introduction
11.8.4 AbbVie Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.8.5 AbbVie Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Oncology Small Molecule Drugs Introduction
11.9.4 Sanofi Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.9.5 Sanofi Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Oncology Small Molecule Drugs Introduction
11.10.4 Takeda Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.10.5 Takeda Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Details
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Oncology Small Molecule Drugs Introduction
11.11.4 Eli Lilly Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.11.5 Eli Lilly Recent Development
11.12 Bayer
11.12.1 Bayer Company Details
11.12.2 Bayer Business Overview
11.12.3 Bayer Oncology Small Molecule Drugs Introduction
11.12.4 Bayer Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.12.5 Bayer Recent Development
11.13 AstraZeneca
11.13.1 AstraZeneca Company Details
11.13.2 AstraZeneca Business Overview
11.13.3 AstraZeneca Oncology Small Molecule Drugs Introduction
11.13.4 AstraZeneca Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.13.5 AstraZeneca Recent Development
11.14 Astellas
11.14.1 Astellas Company Details
11.14.2 Astellas Business Overview
11.14.3 Astellas Oncology Small Molecule Drugs Introduction
11.14.4 Astellas Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.14.5 Astellas Recent Development
11.15 Merck
11.15.1 Merck Company Details
11.15.2 Merck Business Overview
11.15.3 Merck Oncology Small Molecule Drugs Introduction
11.15.4 Merck Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.15.5 Merck Recent Development
11.16 Biogen Idec
11.16.1 Biogen Idec Company Details
11.16.2 Biogen Idec Business Overview
11.16.3 Biogen Idec Oncology Small Molecule Drugs Introduction
11.16.4 Biogen Idec Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.16.5 Biogen Idec Recent Development
11.17 Eisai
11.17.1 Eisai Company Details
11.17.2 Eisai Business Overview
11.17.3 Eisai Oncology Small Molecule Drugs Introduction
11.17.4 Eisai Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.17.5 Eisai Recent Development
11.18 Teva
11.18.1 Teva Company Details
11.18.2 Teva Business Overview
11.18.3 Teva Oncology Small Molecule Drugs Introduction
11.18.4 Teva Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.18.5 Teva Recent Development
11.18 Otsuka
.1 Otsuka Company Details
.2 Otsuka Business Overview
.3 Otsuka Oncology Small Molecule Drugs Introduction
.4 Otsuka Revenue in Oncology Small Molecule Drugs Business (2016-2021)
.5 Otsuka Recent Development
11.20 Ipsen
11.20.1 Ipsen Company Details
11.20.2 Ipsen Business Overview
11.20.3 Ipsen Oncology Small Molecule Drugs Introduction
11.20.4 Ipsen Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.20.5 Ipsen Recent Development
11.21 Gilead Sciences
11.21.1 Gilead Sciences Company Details
11.21.2 Gilead Sciences Business Overview
11.21.3 Gilead Sciences Oncology Small Molecule Drugs Introduction
11.21.4 Gilead Sciences Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.21.5 Gilead Sciences Recent Development
11.22 Exelixis
11.22.1 Exelixis Company Details
11.22.2 Exelixis Business Overview
11.22.3 Exelixis Oncology Small Molecule Drugs Introduction
11.22.4 Exelixis Revenue in Oncology Small Molecule Drugs Business (2016-2021)
11.22.5 Exelixis Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Oncology Small Molecule Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy Drugs
Table 3. Key Players of Immunomodulating Drugs
Table 4. Key Players of Targeted Therapy Drugs
Table 5. Key Players of Hormonal Therapy
Table 6. Key Players of Other
Table 7. Global Oncology Small Molecule Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Oncology Small Molecule Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Oncology Small Molecule Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Oncology Small Molecule Drugs Market Share by Regions (2016-2021)
Table 11. Global Oncology Small Molecule Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Oncology Small Molecule Drugs Market Share by Regions (2022-2027)
Table 13. Oncology Small Molecule Drugs Market Trends
Table 14. Oncology Small Molecule Drugs Market Drivers
Table 15. Oncology Small Molecule Drugs Market Challenges
Table 16. Oncology Small Molecule Drugs Market Restraints
Table 17. Global Oncology Small Molecule Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Oncology Small Molecule Drugs Market Share by Players (2016-2021)
Table 19. Global Top Oncology Small Molecule Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncology Small Molecule Drugs as of 2020)
Table 20. Ranking of Global Top Oncology Small Molecule Drugs Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Oncology Small Molecule Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Oncology Small Molecule Drugs Product Solution and Service
Table 24. Date of Enter into Oncology Small Molecule Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Oncology Small Molecule Drugs Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Oncology Small Molecule Drugs Revenue Market Share by Type (2016-2021)
Table 28. Global Oncology Small Molecule Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Oncology Small Molecule Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Oncology Small Molecule Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Oncology Small Molecule Drugs Revenue Market Share by Application (2016-2021)
Table 32. Global Oncology Small Molecule Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Oncology Small Molecule Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Oncology Small Molecule Drugs Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Oncology Small Molecule Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Oncology Small Molecule Drugs Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Oncology Small Molecule Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Oncology Small Molecule Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Oncology Small Molecule Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Oncology Small Molecule Drugs Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Oncology Small Molecule Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Oncology Small Molecule Drugs Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Oncology Small Molecule Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Oncology Small Molecule Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Oncology Small Molecule Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Oncology Small Molecule Drugs Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Oncology Small Molecule Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Oncology Small Molecule Drugs Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Oncology Small Molecule Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Oncology Small Molecule Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Oncology Small Molecule Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Oncology Small Molecule Drugs Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Oncology Small Molecule Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Oncology Small Molecule Drugs Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Oncology Small Molecule Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Oncology Small Molecule Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Oncology Small Molecule Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Oncology Small Molecule Drugs Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Oncology Small Molecule Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Oncology Small Molecule Drugs Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Oncology Small Molecule Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Oncology Small Molecule Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Oncology Small Molecule Drugs Product
Table 67. Roche Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 68. Roche Recent Development
Table 69. Novartis Company Details
Table 70. Novartis Business Overview
Table 71. Novartis Oncology Small Molecule Drugs Product
Table 72. Novartis Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 73. Novartis Recent Development
Table 74. Pfizer Company Details
Table 75. Pfizer Business Overview
Table 76. Pfizer Oncology Small Molecule Drugs Product
Table 77. Pfizer Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 78. Pfizer Recent Development
Table 79. Celgene Company Details
Table 80. Celgene Business Overview
Table 81. Celgene Oncology Small Molecule Drugs Product
Table 82. Celgene Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 83. Celgene Recent Development
Table 84. Bristol-Myers Squibb Company Details
Table 85. Bristol-Myers Squibb Business Overview
Table 86. Bristol-Myers Squibb Oncology Small Molecule Drugs Product
Table 87. Bristol-Myers Squibb Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 88. Bristol-Myers Squibb Recent Development
Table 89. Amgen Company Details
Table 90. Amgen Business Overview
Table 91. Amgen Oncology Small Molecule Drugs Product
Table 92. Amgen Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 93. Amgen Recent Development
Table 94. Johnson & Johnson Company Details
Table 95. Johnson & Johnson Business Overview
Table 96. Johnson & Johnson Oncology Small Molecule Drugs Product
Table 97. Johnson & Johnson Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 98. Johnson & Johnson Recent Development
Table 99. AbbVie Company Details
Table 100. AbbVie Business Overview
Table 101. AbbVie Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 102. AbbVie Recent Development
Table 103. Sanofi Company Details
Table 104. Sanofi Business Overview
Table 105. Sanofi Oncology Small Molecule Drugs Product
Table 106. Sanofi Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 107. Sanofi Recent Development
Table 108. Takeda Company Details
Table 109. Takeda Business Overview
Table 110. Takeda Oncology Small Molecule Drugs Product
Table 111. Takeda Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 112. Takeda Recent Development
Table 113. Eli Lilly Company Details
Table 114. Eli Lilly Business Overview
Table 115. Eli Lilly Oncology Small Molecule Drugs Product
Table 116. Eli Lilly Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 117. Eli Lilly Recent Development
Table 118. Bayer Company Details
Table 119. Bayer Business Overview
Table 120. Bayer Oncology Small Molecule Drugs Product
Table 121. Bayer Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 122. Bayer Recent Development
Table 123. AstraZeneca Company Details
Table 124. AstraZeneca Business Overview
Table 125. AstraZeneca Oncology Small Molecule Drugs Product
Table 126. AstraZeneca Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 127. AstraZeneca Recent Development
Table 128. Astellas Company Details
Table 129. Astellas Business Overview
Table 130. Astellas Oncology Small Molecule Drugs Product
Table 131. Astellas Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 132. Astellas Recent Development
Table 133. Merck Company Details
Table 134. Merck Business Overview
Table 135. Merck Oncology Small Molecule Drugs Product
Table 136. Merck Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 137. Merck Recent Development
Table 138. Biogen Idec Company Details
Table 139. Biogen Idec Business Overview
Table 140. Biogen Idec Oncology Small Molecule Drugs Product
Table 141. Biogen Idec Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 142. Biogen Idec Recent Development
Table 143. Eisai Company Details
Table 144. Eisai Business Overview
Table 145. Eisai Oncology Small Molecule Drugs Product
Table 146. Eisai Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 147. Eisai Recent Development
Table 148. Teva Company Details
Table 149. Teva Business Overview
Table 150. Teva Oncology Small Molecule Drugs Product
Table 151. Teva Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 152. Teva Recent Development
Table 153. Otsuka Company Details
Table 154. Otsuka Business Overview
Table 155. Otsuka Oncology Small Molecule Drugs Product
Table 156. Otsuka Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 157. Otsuka Recent Development
Table 158. Ipsen Company Details
Table 159. Ipsen Business Overview
Table 160. Ipsen Oncology Small Molecule Drugs Product
Table 161. Ipsen Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 162. Ipsen Recent Development
Table 163. Gilead Sciences Company Details
Table 164. Gilead Sciences Business Overview
Table 165. Gilead Sciences Oncology Small Molecule Drugs Product
Table 166. Gilead Sciences Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 167. Gilead Sciences Recent Development
Table 168. Exelixis Company Details
Table 169. Exelixis Business Overview
Table 170. Exelixis Oncology Small Molecule Drugs Product
Table 171. Exelixis Revenue in Oncology Small Molecule Drugs Business (2016-2021) & (US$ Million)
Table 172. Exelixis Recent Development
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncology Small Molecule Drugs Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Drugs Features
Figure 3. Immunomodulating Drugs Features
Figure 4. Targeted Therapy Drugs Features
Figure 5. Hormonal Therapy Features
Figure 6. Other Features
Figure 7. Global Oncology Small Molecule Drugs Market Share by Application: 2020 VS 2027
Figure 8. Blood Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Gastrointestinal Cancer Case Studies
Figure 11. Prostate Cancer Case Studies
Figure 12. Lung Cancer Case Studies
Figure 13. Other Case Studies
Figure 14. Oncology Small Molecule Drugs Report Years Considered
Figure 15. Global Oncology Small Molecule Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Oncology Small Molecule Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Oncology Small Molecule Drugs Market Share by Regions: 2020 VS 2027
Figure 18. Global Oncology Small Molecule Drugs Market Share by Regions (2022-2027)
Figure 19. Global Oncology Small Molecule Drugs Market Share by Players in 2020
Figure 20. Global Top Oncology Small Molecule Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncology Small Molecule Drugs as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Oncology Small Molecule Drugs Revenue in 2020
Figure 22. Global Oncology Small Molecule Drugs Revenue Market Share by Type (2016-2021)
Figure 23. Global Oncology Small Molecule Drugs Revenue Market Share by Type (2022-2027)
Figure 24. North America Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Oncology Small Molecule Drugs Market Share by Type (2016-2027)
Figure 26. North America Oncology Small Molecule Drugs Market Share by Application (2016-2027)
Figure 27. North America Oncology Small Molecule Drugs Market Share by Country (2016-2027)
Figure 28. United States Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Oncology Small Molecule Drugs Market Share by Type (2016-2027)
Figure 32. Europe Oncology Small Molecule Drugs Market Share by Application (2016-2027)
Figure 33. Europe Oncology Small Molecule Drugs Market Share by Country (2016-2027)
Figure 34. Germany Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Oncology Small Molecule Drugs Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Oncology Small Molecule Drugs Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Oncology Small Molecule Drugs Market Share by Region (2016-2027)
Figure 44. China Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Oncology Small Molecule Drugs Market Share by Type (2016-2027)
Figure 52. Latin America Oncology Small Molecule Drugs Market Share by Application (2016-2027)
Figure 53. Latin America Oncology Small Molecule Drugs Market Share by Country (2016-2027)
Figure 54. Mexico Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Oncology Small Molecule Drugs Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Oncology Small Molecule Drugs Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Oncology Small Molecule Drugs Market Share by Country (2016-2027)
Figure 60. Turkey Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Oncology Small Molecule Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Roche Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 64. Novartis Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 65. Pfizer Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 66. Celgene Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 67. Bristol-Myers Squibb Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 68. Amgen Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 69. Johnson & Johnson Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 70. AbbVie Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 71. Sanofi Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 72. Takeda Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 73. Eli Lilly Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 74. Bayer Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 75. AstraZeneca Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 76. Astellas Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 77. Merck Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 78. Biogen Idec Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 79. Eisai Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 80. Teva Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 81. Otsuka Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 82. Ipsen Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 83. Gilead Sciences Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 84. Exelixis Revenue Growth Rate in Oncology Small Molecule Drugs Business (2016-2021)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed
世界の非小細胞肺がん治療薬市場規模・現状・予測（2021年-2027年） Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drug…- 非小細胞肺がん薬のグローバル市場：規模・現状・予測2019-2025 Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drugs…
- 非小細胞肺がん薬のグローバル市場：規模・現状・予測2019-2025 Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drugs…
- 世界のがん支持療法薬剤市場規模・現状・予測（2021年-2027年） Supportive drugs are not anticancer drugs. They protect certain cells or organs from the side effects of chemotherapy drugs or radiation therapy. Increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailore…
- LAMEA腫瘍/抗癌剤のグローバル市場調査 2019年 The global LAMEA Oncology/Anti-cancer drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on LAMEA Oncology/Anti-cancer drugs volume and value at global level, regional level and company level. From …